Pentoxifylline as Adjuvant Therapy to Etanercept in Patients with Moderately to Highly Active heumatoid Arthritis: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

    9 August 2022

    • curprev 03:5203:52, 9 August 2022‎ 179.215.124.0 talk‎ 488 bytes +488‎ Created page with "== Target Article == Pentoxifylline as Adjuvant Therapy to Etanercept in Patients with Moderately to Highly Active heumatoid Arthritis; SI Mohammed, FI Gorialae; 2013; doi_citing_unknown == Retraction == The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells.; Jiyeon S. Kim, Jennifer E. Smith-Garvin, Gary A. Koretzky, and Martha S. Jordan; 2011 ; https://doi.org/10.1084/jem.20110680 == Citation piece == Note: Open to append..."
Retrieved from "https://wikicitingretracted.org/index.php?title=Pentoxifylline_as_Adjuvant_Therapy_to_Etanercept_in_Patients_with_Moderately_to_Highly_Active_heumatoid_Arthritis"